Purpose: Individuals with schizophrenia have a vastly reduced lifespan compared with the general population; comorbid cardiovascular disease (CVD) is the leading cause of death for them. Furthermore, these individuals are more likely to have metabolic syndrome-related disorders (MSDs), which increase CVD risk. We examined the medical records of long-term inpatients with schizophrenia to identify methods for preventing CVD and MSDs. Method: A retrospective survey was conducted on 56 inpatients with schizophrenia. The prevalence rates of CVD and MSDs among inpatients with schizophrenia were compared with Japanese general population data from the 2010 National Health and Nutrition Examination Survey. Then, we compared the variables influencing CVD and MSDs between first-and second-generation antipsychotic drug groups. Results: The prevalence of hyperlipidemia, diabetes mellitus, hypertension, myocardial infarction, and cerebral hemorrhage among individuals with schizophrenia was lower than that among the Japanese general population. This effect is likely attributable to the nursing care offered to individuals with schizophrenia, which includes dietary advice, moderate exercise support, and body weight and blood pressure measurement. Medication did not correlate with CVD or MSD prevalence. Discussion: Long-term hospitalization appeared to be particularly useful in preventing CVD and MSDs; thus, nursing care equivalent to that provided in hospitals can reduce the prevalence of CVD and MSDs among patients with schizophrenia. Antipsychotic drugs might have only a minor influence on CVD and MSD prevalence with reliable nursing care. Japanese psychiatric personnel should attend to outpatients with schizophrenia, as this population is increasing and receives less care than do inpatients.
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Abstract Objectives: Relapse of psychotic symptoms deteriorate the clinical course of schizophrenia. This study investigated the association between the medication adherence and rehospitalization in relapsed patients with schizophrenia who had been discharged after improving psychotic symptoms. Methods: A total of 120 patients with schizophrenia who rehospitalized because of relapse of psychotic symptoms were consecutively enrolled in Seoul National Hospital between June 2015 and November 2015. We investigated the medication adherence, reason for nonadherence, medication change during the OPD follow-up.
Results:
The clinical courses of relapsed patients fell into three distinct groups; the good adherence group (N=52, 43.3%), the poor adherence group (N=45, 37.5%), and the nonadherence group (N=23, 19.2%). In comparison, the three groups showed significant differences in the duration of illness, duration of previous hospitalizations, insurance forms Intellectual functioning was also assessed using by Wechsler intelligence scale (IQ). Results: UHR individuals were found to have higher hostility perception bias (p<0.001) and blame bias (p< 0.001) compared to normal controls. Preliminary correlation analysis in UHR individuals showed that hostility perception bias was correlated with trait anxiety (r=0.49, uncorrected p<0.001) and low self-esteem (r=-0.33, uncorrected p=0.010) while hostility bias was not correlated with verbal (r=-0.18, uncorrected p=0.173) and performance (r=-0.9, uncorrected p=0.523) IQ. The blame bias was linked to trait anxiety (r=0.5, uncorrected p<0.001), low self-esteem (r=-0.54, uncorrected p<0.001) and verbal IQ (r=-0.26, p=0.045). Linear regression analysis revealed that hostility We tested the applicability of a previously-developed paliperidone palmitate 3-month (PP3M) population pharmacokinetic (pop-PK) model to PK data from Chinese and Japanese patients from a global PP3M phase-3 study (NCT01515423). A pharmacokinetic/pharmacodynamic (PK/PD) model was developed to describe the relationship between time course of paliperidone plasma concentrations following PP3M administration and relapse rates, as well as relevant risk factors. Methods: PK data from 1369 patients were used for external validation of a pop-PK model 1 previously developed on data from phase-1 and phase-3 studies 2, 3 . Relevant covariate effects were body mass index (BMI) on volume of distribution; creatinine clearance on renal clearance; injection site, sex, injection volume on absorption parameters. The PK/PD analysis dataset included 1002 patients who were randomized to receive PP1M or PP3M in the double-blind phase.
The pop-PK model was successfully validated on the new PK data. No model refinement was needed to describe Chinese and Japanese PK data. PK/PD modeling showed that higher paliperidone exposure was associated with reduced relapse risk, with no major differences in relapse rates between PP1M and PP3M arms. Independently from paliperidone exposure, higher relapse hazard was identified for patients on concomitant benzodiazepine medication (+193% hazard; 95% confidence interval: 85-363%), and patients at Japanese centers (+129% hazard; 95% confidence interval: 36-283%).
Conclusions:
The previously-developed pop-PK model and covariates adequately captured the PK of PP3M from the current study. Race did not influence PP3M pharmacokinetics after the impact of BMI was incorporated in the model. PK/PD modeling of relapse rates evidenced an exposure-response relationship, i.e. reduced risk of relapse for higher paliperidone concentrations. Concomitant benzodiazepine use (possibly to treat residual/emergent symptoms) may be interpreted as an indicator of higher patient severity, and hence higher risk of relapse. In model-based simulations, the PP1M and PP3M arms appeared to display similar relapse rates over time.
